Khosla Ventures is a venture capital firm established in 2004 by Vinod Khosla, co-founder of Sun Microsystems, and is headquartered in Menlo Park, California. The firm manages over $5 billion and focuses on investing in a diverse range of sectors, including consumer technology, enterprise solutions, education, healthcare, financial services, agriculture, sustainable energy, and robotics. Khosla Ventures provides not only capital but also strategic guidance to entrepreneurs, particularly in early-stage ventures, where it often supports innovative and unconventional projects. The firm seeks to back companies that are driven by breakthrough technologies, with investment sizes ranging from $100,000 to over $20 million. Khosla Ventures maintains a collaborative approach, frequently co-investing with other firms, including Kleiner Perkins, with which it has historical ties.
IgGenix, Inc. is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of food and other severe allergies. Founded in 2019 and based in South San Francisco, California, the company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies. This process aims to alleviate and prevent allergic reactions by suppressing the allergic cascade. IgGenix captures and analyzes rare human B cells that produce allergen-binding antibodies and engineers these cells to enhance their immune-modulating properties. By addressing critical needs in the medical industry, IgGenix seeks to provide effective solutions for life-threatening allergic reactions.
Genecis is an early-stage organic waste processing startup that uses biotechnology to convert waste into biodegradeable plastics and other high value materials. Genecis is headquartered in Scarborough, Canada.
IgGenix, Inc. is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of food and other severe allergies. Founded in 2019 and based in South San Francisco, California, the company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies. This process aims to alleviate and prevent allergic reactions by suppressing the allergic cascade. IgGenix captures and analyzes rare human B cells that produce allergen-binding antibodies and engineers these cells to enhance their immune-modulating properties. By addressing critical needs in the medical industry, IgGenix seeks to provide effective solutions for life-threatening allergic reactions.
EGenesis Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York. Founded in 2015, the company specializes in gene editing and genome engineering, focusing on the development of human-compatible organs, tissues, and cells for transplantation. EGenesis employs advanced gene editing techniques to create transplantable cells and solid organs, specifically targeting therapeutic applications in kidney and islet cell transplantation. By leveraging its innovative platform, the company aims to transform the field of organ transplantation, providing safe and effective solutions for patients with life-threatening diseases globally.
IgGenix, Inc. is a biotechnology company focused on developing innovative antibody therapeutics for the treatment of food and other severe allergies. Founded in 2019 and based in South San Francisco, California, the company specializes in isolating and transforming allergen-specific IgE antibodies into IgG antibodies. This process aims to alleviate and prevent allergic reactions by suppressing the allergic cascade. IgGenix captures and analyzes rare human B cells that produce allergen-binding antibodies and engineers these cells to enhance their immune-modulating properties. By addressing critical needs in the medical industry, IgGenix seeks to provide effective solutions for life-threatening allergic reactions.
EGenesis Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York. Founded in 2015, the company specializes in gene editing and genome engineering, focusing on the development of human-compatible organs, tissues, and cells for transplantation. EGenesis employs advanced gene editing techniques to create transplantable cells and solid organs, specifically targeting therapeutic applications in kidney and islet cell transplantation. By leveraging its innovative platform, the company aims to transform the field of organ transplantation, providing safe and effective solutions for patients with life-threatening diseases globally.
Gen1E Lifesciences is a developer of a platform designed to accelerate cures for inflammatory and age-related diseases.The company's services include a pipeline of preclinical stage products that includes a P38 kinase inhibitor for the treatment of various inflammatory diseases, enabling medical researchers to optimize existing regulatory incentives, reduce the required R&D time and cost, truncate the time to exit and improve the success rate in receiving FDA approval and commercial success.
Probably Genetic is dedicated to assisting individuals with rare genetic conditions that are often misdiagnosed as autism spectrum disorder. Typically, patients endure an exhausting wait of up to seven years to receive accurate diagnoses, leading to significant emotional and financial burdens as they consult numerous doctors and specialists. To address this issue, Probably Genetic provides educational resources and DNA sequencing tests, facilitating a more straightforward path to understanding whether there may be underlying genetic factors contributing to their symptoms. The organization's goal is to support those who are overlooked by the existing healthcare system, ultimately helping families find clarity and answers more efficiently.
EGenesis Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York. Founded in 2015, the company specializes in gene editing and genome engineering, focusing on the development of human-compatible organs, tissues, and cells for transplantation. EGenesis employs advanced gene editing techniques to create transplantable cells and solid organs, specifically targeting therapeutic applications in kidney and islet cell transplantation. By leveraging its innovative platform, the company aims to transform the field of organ transplantation, providing safe and effective solutions for patients with life-threatening diseases globally.
YuMe is a provider of digital video brand advertising solutions that drives inventory monetization and enables advertisers to reach targeted audiences across a wide range of internet-connected devices. Designed to serve the specific needs of brand advertising, its technology platform simplifies the complexities associated with delivering effective digital video advertising campaigns in today’s market.
YuMe was founded in 2004 by [Jayant Kadambi](https://www.crunchbase.com/person/jayant-kadambi#/entity) and [Ayyappan Sankaran](https://www.crunchbase.com/person/ayyappan-sankaran#/entity). It is headquartered in Redwood City, C.A. with European headquarters in London and nine additional offices worldwide.
GroupMe Inc. is a New York-based company that develops and operates a group messaging application accessible via smartphones, push notifications, or SMS. Founded in 2010, the platform allows users to communicate in groups effortlessly, enabling anyone from their contact list to join conversations without requiring a smartphone. GroupMe facilitates connections among friends, family, and coworkers, making it a versatile tool for maintaining relationships. The company gained significant attention by processing billions of messages and receiving the Breakout award at SXSW. In 2011, GroupMe was acquired and became a subsidiary of Skype Global, yet it continues to function with a degree of autonomy, fostering an entrepreneurial environment among its team.
YuMe is a provider of digital video brand advertising solutions that drives inventory monetization and enables advertisers to reach targeted audiences across a wide range of internet-connected devices. Designed to serve the specific needs of brand advertising, its technology platform simplifies the complexities associated with delivering effective digital video advertising campaigns in today’s market.
YuMe was founded in 2004 by [Jayant Kadambi](https://www.crunchbase.com/person/jayant-kadambi#/entity) and [Ayyappan Sankaran](https://www.crunchbase.com/person/ayyappan-sankaran#/entity). It is headquartered in Redwood City, C.A. with European headquarters in London and nine additional offices worldwide.
YuMe is a provider of digital video brand advertising solutions that drives inventory monetization and enables advertisers to reach targeted audiences across a wide range of internet-connected devices. Designed to serve the specific needs of brand advertising, its technology platform simplifies the complexities associated with delivering effective digital video advertising campaigns in today’s market.
YuMe was founded in 2004 by [Jayant Kadambi](https://www.crunchbase.com/person/jayant-kadambi#/entity) and [Ayyappan Sankaran](https://www.crunchbase.com/person/ayyappan-sankaran#/entity). It is headquartered in Redwood City, C.A. with European headquarters in London and nine additional offices worldwide.
YuMe is a provider of digital video brand advertising solutions that drives inventory monetization and enables advertisers to reach targeted audiences across a wide range of internet-connected devices. Designed to serve the specific needs of brand advertising, its technology platform simplifies the complexities associated with delivering effective digital video advertising campaigns in today’s market.
YuMe was founded in 2004 by [Jayant Kadambi](https://www.crunchbase.com/person/jayant-kadambi#/entity) and [Ayyappan Sankaran](https://www.crunchbase.com/person/ayyappan-sankaran#/entity). It is headquartered in Redwood City, C.A. with European headquarters in London and nine additional offices worldwide.
YuMe is a provider of digital video brand advertising solutions that drives inventory monetization and enables advertisers to reach targeted audiences across a wide range of internet-connected devices. Designed to serve the specific needs of brand advertising, its technology platform simplifies the complexities associated with delivering effective digital video advertising campaigns in today’s market.
YuMe was founded in 2004 by [Jayant Kadambi](https://www.crunchbase.com/person/jayant-kadambi#/entity) and [Ayyappan Sankaran](https://www.crunchbase.com/person/ayyappan-sankaran#/entity). It is headquartered in Redwood City, C.A. with European headquarters in London and nine additional offices worldwide.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.